Change of extracellular glutamate and GABA level in striatum during deep brain stimulation of the entopeduncular nucleus in rats
Objective: Globus pallidus interna (GPi) is recognized as an effective treatment for advanced Parkinson’s disease. However, the neurochemical basis of its effects remains unknown. The…Relationship between symptoms and regional density of metabotropic glutamate receptors subtype 1 measured with 11C-ITMM PET in de novo Parkinson’s disease
Objective: To investigate correlations of motor and non-motor symptoms with the brain densitiesof the metabotropic glutamate receptor subtype 1 (mGluR1) in de novo Parkinson’s disease…Serum glutamate is associated with the motor subtype of Parkinson’s disease
Objective: We aimed to study the concentration of glutamate in the serum of patients with Parkinson's disease (PD) and its connection with clinical variants of…Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson’s Disease
Objective: To evaluate whether safinamide inhibits in vivo glutamate (Glu) release in a rodent model of Parkinson’s disease (PD), i.e. the 6-hydroxydopamine (6-OHDA) hemilesioned rat.…A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID
Objective: Objective was to assess the therapeutic potential of our novel mGlu4 positive allosteric modulator (PAM), foliglurax, as an anti-parkinsonian treatment in gold-standard primate models.…Use of safinamide: A clinical practice review of 2 year experience
Objective: Review the clinical use, efectivity and side efects in a population based cohort. Background: Safinamide is an oral, once a day adjunctive therapy for…Ocular motor function in stiff person syndrome – Role of GABA and beyond
Objective: Delineate pathophysiology of gaze-holding function in stiff person syndrome (SPS). Background: Glutamic acid decarboxylase (GAD) catalyzes conversion of glutamate to gamma-aminobutyric acid (GABA). Anti-GAD…Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease
Objective: We aimed to study the association between glutamatergic system gene polymorphisms (SLC1A2 – gene, coding excitatory acids transporter, and GRIN2A gene, coding a subunit…Alterations of cortical metabotropic glutamate receptor-mediated signaling in patients with Parkinson’s disease
Objective: To evaluate expression of brain metabotropic glutamatergic receptor 5 and the relationship with clinical measures in Parkinson’s disease patients. Background: Metabotropic glutamate receptor 5…Anti-glutamatergic effect of safinamide in Parkinson’s Disease: A TMS study
Objective: To test the effect of safinamide, at the doses of 50 and 100 mg/day, on primary motor cortex (M1) excitability and glutamatergic neurotransmission in…